NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy ...

The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the ...

Ajinomoto launches CELLiST AAV Production Supplement 1, boosting gene therapy viral vector productivity by 1.3-2x.

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ...

This year saw notable progress in head and neck cancers, Huntington's disease, personalized genetic therapy, and heart ...

Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults ...

The FDA approved Itvisma gene therapy for patients aged 2 years and older with spinal muscular atrophy and confirmed SMN1 gene mutation.

Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Product designation ...

OverviewThe global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal ...